Phase 1/2 RAS Inhibitor Results Published in NEJM Group

Seeing our Phase 1/2 data published in the NEJM is a proud milestone — and more importantly, a foundation we're building on at scale. These results helped shape the scientific rationale for RASolute 302 and the three additional Phase 3 trials now underway across PDAC and RAS mutant non-small cell lung cancer. From early signal to global registrational program. That's the work. #RAS(ON) #Oncology #PancreaticCancer #NSCLC #RevMed

Encouraging to see Phase 1/2 clinical data for daraxonrasib published in NEJM Group. Alongside recent FDA authorization of an expanded access program for patients with metastatic #PancreaticCancer this is an exciting moment. Through our collaboration with Revolution Medicines and The Lustgarten Foundation, Break Through Cancer is supporting a dedicated cohort within an ongoing Phase 1/2 study designed to generate deeply profiled datasets to better understand response, resistance, and next-generation strategies for RAS-targeted therapies.

Pleased to see the NEJM publication of the Phase 1/2 study evaluating daraxonrasib in metastatic PDAC. Early-phase development informing late-phase trial design, as intended. Deep gratitude to the patients, caregivers, investigators and study teams whose commitment made this work possible.

Today we announced updated Phase 1 data for our RAS(ON) G12D-selective inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer at the American Association for Cancer Research Annual Meeting. These updated data further strengthen the profile of our RAS(ON) G12D-selective inhibitor as a potentially important targeted therapy for patients with RAS G12D non-small cell lung cancer, a population with significant unmet medical need. Learn more: https://lnkd.in/gkCPAdWm #AACR26 #LungCancer

Congratulations to our friends at Revolution Medicines on their exciting updated phase 1 data. Fantastic news! These advanced therapies require well-controlled and validated supply chains from point of manufacture to point of care. We at Modality Solutions, A BlueRidge Life Sciences Company can help. Reach out if you have any questions on your #biopharma #coldchainlogistics challenges. #AACR26 #LungCancer #AdvancedTherapies #ColdChainEngineering

New clinical trial results presented at the American Association for Cancer Research (AACR) Annual Meeting are raising hopes for patients with pancreatic cancer, which has long been one of the most dire diagnoses in oncology. Researchers are becoming cautiously optimistic that the RAS inhibitor daraxonrasib could transform pancreatic cancer treatment in the same way that the approval of herceptin in 1998 reshaped breast cancer from a near-term death sentence into—in many cases—a chronic disease. “It’s just the beginning of the role of all types of inhibitors of the RAS pathway in making major impacts in the clinic,” said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center and AACR president-elect. Endpoints News #AACR26

AACR Update! In an oral presentation, Synthekine presented updated clinical and translational data for STK-012, a first-in-class α/β IL-2 receptor‑biased partial agonist, in combination with pembrolizumab, pemetrexed, and carboplatin in first-line PD-L1-negative, non‑squamous non-small cell lung cancer (NSCLC). The data underscores the potential for STK-012 to improve outcomes for some of the hardest-to-treat patients with lung cancer. You can read more here: https://lnkd.in/g3h22Tif 

Updates from #ESMOBreast26: Paolo Tarantino, MD, Dana-Farber Cancer Institute, discusses results from the phase 2 #SATEEN trial evaluating sacituzumab govitecan plus #trastuzumab in heavily pretreated patients with #HER2-positive metastatic breast cancer. These findings suggest limited benefit of sequential #TOP1 antibody drug conjugates in this setting and highlight the need for optimized #sequencing strategies in #HER2-positive breast cancer. Learn more: https://lnkd.in/eRjybTWU

I just saw this featured on TV — very encouraging news in the fight against pancreatic cancer. Has anyone else heard about this breakthrough or been following the research? The attention is coming from recent clinical trials of a KRAS-targeting drug (daraxonrasib), which showed patients lived longer compared to standard chemotherapy. KRAS has long been considered “undruggable,” so this represents meaningful progress. It’s still early, and mainly for advanced cases, but it’s an important development in pancreatic cancer research.

The Benefits of Prostate Cancer Screening Outweigh the Harms, According to New Patient Guidelines From NCCN https://lnkd.in/gVMa9gHW Free, comprehensive guidebook shows how prostate cancer screening has largely deemphasized invasive testing in order to avoid unnecessary procedures and treatment while at the same time saving lives. PLYMOUTH MEETING, Pa., April 28, 2026 /PRNewswire/ [...]